Navigation Links
Generic Biologics – U.S Panel Hearing Draws Mixed Response

There are varied reactions to the U.S panel hearing that cheaper versions of biologic drugs// can be manufactured.

The Senate Health, Education, Labor and Pensions Committee is considering legislation that would give the Food and Drug Administration legal authority to approve alternative versions of expensive biologic drugs after patents expire.

Yet it has drawn both brickbats and accolades from various sections.

Says Jay Siegel, head of research for Johnson & Johnson's biotechnology business: ' You just can't take a molecule that you don't know what it is and market it to the people. It's too risky.'

He opines that rival products also known as follow-on biologics should be put up for extensive clinic studies and post approval studies before approval.

Nicolas Rossignol, who oversees implementation of the European Commission’s legislation on biosimilars, told the panel some biologics like insulin and human growth hormones are fairly simple to produce as generics, but that other more complex biologic drugs cannot be reliably duplicated. In general, European regulators advise caution.

Ajaz Hussain, who oversees biological drugs for Novartis AG's generics unit Sandoz,in contrast says science reveals that follow-on biologics can treat the same conditions as their more expensive counterparts.

'FDA already has the expertise' to review them, he told the panel. 'What you need to do is to empower them to act.'

His feelings are echoed by AARP (representing millions of American seniors, and America's Health Insurance Plans) President Erik Olsen:'A therapy is only helpful to the patient who has access to it.

'Biologics hold great promise for treating serious diseases such as cancer, multiple sclerosis, anemia and rheumatoid arthritis, but when some treatments cost thousands of dollars per dose, many patients cannot afford to fill their prescriptions.

'Science has progressed to t he point where it is possible to create generic biologics and to do so safely. All FDA lacks is the authority to approve these therapies,' he added.

The repercussions of the decision will extend to other areas.

Employers and insurers see this development as a means to curb skyrocketing health care cost.

In addition to private health providers, the U.S. government, which runs the Medicare and Medicaid insurance programs for the elderly, disabled and poor, also stands to save millions of dollars.

While different politic parties support diverse views, Sen. Mike Enzi, Wyoming Republican advises caution, ' Any time we start legislating on complex scientific issues and don't know all the facts, we risk endangering lives.'
ANN
'"/>




Related medicine news :

1. Generic drug costs remain shackled
2. FDA Approves Indian Generic Drug For AIDS Treatment
3. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
4. AIDS Generic Drugs Approved by FDA for Sale in US
5. HIV Mortality declining in India due to Generic Antiretroviral therapy drugs
6. Generic Drugs Usage In US Can Save $20 Billion – Express Script Surve
7. Generic Products Compete With GlaxoSmithKline
8. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
9. Ranbaxy Expands By Acquiring A Generic Company In Belgium
10. First Generic Version of Lexapro permitted by US
11. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/29/2016)... -- Automation is one of the best ... growing demands for productivity in speed, accuracy, throughput and ... already adept of a wide range of functions that ... Instrumentation continues to evolve, and is poised to tackle ... years ago. Originally used mostly by the big pharmaceutical ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
Breaking Medicine Technology: